168 related articles for article (PubMed ID: 38238320)
1. Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21.
Sui Y; Liu Q; Xu C; Ganesan K; Ye Z; Li Y; Wu J; Du B; Gao F; Song C; Chen J
Cell Death Dis; 2024 Jan; 15(1):67. PubMed ID: 38238320
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
Zhao C; Liu L; Liu Q; Li F; Zhang L; Zhu F; Shao T; Barve S; Chen Y; Li X; McClain CJ; Feng W
Mol Metab; 2019 Nov; 29():145-157. PubMed ID: 31668386
[TBL] [Abstract][Full Text] [Related]
4. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet.
Singhal G; Kumar G; Chan S; Fisher FM; Ma Y; Vardeh HG; Nasser IA; Flier JS; Maratos-Flier E
Mol Metab; 2018 Jul; 13():56-66. PubMed ID: 29753678
[TBL] [Abstract][Full Text] [Related]
6.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
7. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling.
Liu X; Zhang Y; Ma C; Lin J; Du J
Mol Biol Rep; 2022 Apr; 49(4):3113-3122. PubMed ID: 35107741
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
Rusli F; Deelen J; Andriyani E; Boekschoten MV; Lute C; van den Akker EB; Müller M; Beekman M; Steegenga WT
Sci Rep; 2016 Jul; 6():30484. PubMed ID: 27470139
[TBL] [Abstract][Full Text] [Related]
9. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
[TBL] [Abstract][Full Text] [Related]
10. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.
Qiu H; Song E; Hu Y; Li T; Ku KC; Wang C; Cheung BMY; Cheong LY; Wang Q; Wu X; Hoo RLC; Wang Y; Xu A
Cell Mol Gastroenterol Hepatol; 2022; 14(5):1003-1023. PubMed ID: 35931383
[TBL] [Abstract][Full Text] [Related]
12. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk.
Liu Y; Dou X; Zhou WY; Ding M; Liu L; Du RQ; Guo L; Qian SW; Tang Y; Yang QQ; Pan DN; Li XY; Lu Y; Cheng JK; Tang QQ
Hepatology; 2021 Oct; 74(4):1864-1883. PubMed ID: 33934381
[TBL] [Abstract][Full Text] [Related]
15. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury.
Desai BN; Singhal G; Watanabe M; Stevanovic D; Lundasen T; Fisher FM; Mather ML; Vardeh HG; Douris N; Adams AC; Nasser IA; FitzGerald GA; Flier JS; Skarke C; Maratos-Flier E
Mol Metab; 2017 Nov; 6(11):1395-1406. PubMed ID: 29107287
[TBL] [Abstract][Full Text] [Related]
18. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M
Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645
[TBL] [Abstract][Full Text] [Related]
19. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway.
Wang ZQ; Zhang XH; Yu Y; Tipton RC; Raskin I; Ribnicky D; Johnson W; Cefalu WT
Metabolism; 2013 Sep; 62(9):1239-49. PubMed ID: 23702383
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice.
Gong Q; Hu Z; Zhang F; Cui A; Chen X; Jiang H; Gao J; Chen X; Han Y; Liang Q; Ye D; Shi L; Chin YE; Wang Y; Xiao H; Guo F; Liu Y; Zang M; Xu A; Li Y
Hepatology; 2016 Aug; 64(2):425-38. PubMed ID: 26926384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
